Computational drug design for an HIV cure.
We design small molecules that reactivate latently infected cells — directly attacking the viral reservoir that current antiretroviral therapy cannot reach.
An AI-native approach to a true HIV cure.
Mechanism-based design
Our chemistry targets a specific molecular bottleneck that holds HIV in its latent state — a mechanism grounded in stochastic systems modeling of the host–virus transcriptional circuit.
AI-driven computational platform
Generative diffusion models, all-atom molecular dynamics, and structure-based design on dedicated GPU infrastructure, calibrated against the deposited structural biology of the HIV transcriptional machinery — so each candidate is de-risked in silico before a single molecule is synthesized.
Translational discipline
Designed from day one for the eradication endpoint — full clearance of the latent reservoir — and for integration with complementary kill-leg agents to enable a true HIV cure.
A focused path to a cure.
Cure Dynamics is a privately held biotechnology company focused on HIV cure research. We are pursuing a non-dilutive funding strategy alongside selective private investment to advance our lead program through preclinical proof-of-concept.
Investor inquiries Learn about the scienceClosing the gap between the biology and the chemistry of cure.
An estimated 40 million people worldwide live with HIV-1, and every one of them needs lifelong antiretroviral therapy (ART) to keep the virus suppressed — today about 32 million receive it. ART has been transformative — HIV is no longer a death sentence — but it does not eliminate the disease. Long-lived memory T cells that harbor silent integrated virus, the latent reservoir, persist for the patient's lifetime. The day ART stops, the virus returns.
Curing HIV requires eliminating the reservoir itself. The dominant approach — "shock and kill" — reactivates the dormant virus so infected cells become visible to immune effectors or selective cytotoxic agents. The biology has been understood for over a decade. The medicinal chemistry, until now, has not delivered.
Cure Dynamics was founded to close that gap. We design small molecules that reactivate latently infected cells through a mechanism specific to HIV transcription, and we design them to be compatible with the most promising kill-leg agents. The endpoint is an eradication cure.
"HIV is unusual — the biology of a cure is well understood, while the chemistry of a cure remains unsolved. We focus where computational chemistry can move the field."
Three disciplines, designed to work as one system.
Our drug-design platform combines three disciplines that, taken together, allow us to design small molecules against a mechanism that prior drug-discovery campaigns could not address.
Stochastic systems modeling of HIV latency.
The transition from latent to actively replicating HIV is a probabilistic event governed by the stochastic dynamics of an intracellular gene-regulatory circuit. Mathematical models of this circuit — developed in part by Cure Dynamics' founder during his prior academic and research career¹ — identify specific molecular bottlenecks whose perturbation collapses the latent state most efficiently.
AI-driven generative chemistry.
Diffusion-based generative models for pocket-conditioned ligand design, scaffold hopping, and linker generation produce candidate molecules at scale. Each candidate is evaluated through a triage pipeline of physics-based pose refinement, free-energy perturbation, and pharmacokinetic-property modeling on dedicated GPU infrastructure.
Structural-biology-informed design.
All compound design is anchored to the deposited structures of the HIV transcriptional machinery and to long-timescale all-atom molecular dynamics. Graph-neural-network cryptic-pocket detection, validated against published structural data, identifies druggable surfaces not visible in any single static structure.
Translational coupling.
The same probability-landscape framework that motivates target selection also drives the PK/PD and mechanistic models that links molecular potency to predicted reservoir-decay kinetics — the endpoint that ultimately matters to patients, regulators, and reviewers.
Lead program
A small-molecule latency-reversing agent designed to reactivate HIV transcription through a mechanism distinct from any prior LRA class.
Specific composition of matter, mechanism of action, and target chemistry are confidential pending intellectual-property prosecution.
¹ Cao Y, Lei X, Ribeiro RM, Perelson AS, Liang J. "Probabilistic control of HIV latency and transactivation by the Tat gene circuit." PNAS 2018, 115(49):12453–12458. doi:10.1073/pnas.1811195115
Built on a quantitative foundation.
Scientific Advisory Board (forming)
Cure Dynamics is assembling its Scientific Advisory Board across HIV virology, computational structural biology, medicinal chemistry, and translational HIV research. Inquiries welcome.
Let's talk.
For investors
We welcome introductions from venture, family-office, and strategic biotech investors with focus in HIV, infectious disease, or computational drug design.
investors@cure-dynamics.comScientific collaboration
We pursue collaborations in latency biology, primary-cell reservoir assays, and structural biology of HIV transcription.
science@cure-dynamics.com